News >

FDA Accepts Application for Rituximab Biosimilar

Jason Harris
Published: Tuesday, Sep 12, 2017

The FDA has accepted a biologics license application (BLA) for the rituximab (Rituxan) biosimilar Rixathon (GP2013), according to Sandoz (Novartis), the company developing the treatment.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication